levetiracetam sold brand name keppra among others medication used treat used partialonset myoclonic seizures taken either mouth immediate extended release formulation injection common side effects levetiracetam include sleepiness dizziness feeling tired severe side effects may include psychosis suicide allergic reactions syndrome levetiracetam senantiomer mechanism action yet levetiracetam approved medical use united states available generic commonly prescribed medication united states million world health organizations list essential levetiracetam effective singledrug treatment newly diagnosed focal epilepsy reduces focal seizures addon levetiracetam effective addon treatment partial focal levetiracetam effective treatment generalized tonicclonic approved united states addon treatment myoclonic tonicclonic levetiracetam approved european union monotherapy treatment epilepsy case partial seizures adjunctive therapy partial myoclonic tonicclonic levetiracetam sometimes used label treat status based lowquality evidence levetiracetam effective phenytoin prevention early seizures traumatic brain may effective prevention seizures associated subarachnoid levetiracetam found useful treatment neuropathic treatment essential levetiracetam found useful treating developmental disorders within autism studies proven effective treatment partial myoclonic tonicclonic seizures associated autism spectrum studies female pregnant rats shown minor fetal skeletal abnormalities given maximum recommended human doses levetiracetam orally throughout pregnancy lactationmedical citation needed studies conducted look increased adverse effects elderly population compared younger patients one study published epilepsy research showed significant increase incidence adverse symptoms experienced young elderly patients central nervous system cns disordersmedical citation needed common adverse effects levetiracetam treatment include cns effects somnolence decreased energy headache dizziness mood swings coordination difficulties adverse effects pronounced first month therapy patients dropped preapproval clinical trials due side people taking levetiracetam experience adverse neuropsychiatric symptoms usually mild include agitation hostility apathy anxiety emotional lability depression serious psychiatric adverse side effects reversed drug discontinuation occur include hallucinations suicidal thoughts psychosis occurred mostly within first month therapy could develop time although rare syndrome sjs toxic epidermal necrolysis ten appears painful spreading rash redness blistering andor peeling skin reported patients treated incidence sjs following exposure antiepileptics levetiracetam levetiracetam used people previously shown hypersensitivity levetiracetam inactive ingredients tablet oral solution hypersensitivity reactions include limited unexplained rash redness blistered skin difficulty breathing tightness chest study incidence decreased bone mineral density patients levetiracetam significantly higher epileptic levetiracetam along antiepileptic drugs increase risk suicidal behavior thoughts people taking levetiracetam monitored closely signs worsening depression suicidal thoughts tendencies altered emotional behavioral kidney impairment decreases rate elimination levetiracetam body individuals reduced kidney function may require dose adjustments kidney function estimated rate creatinine dose adjustment levetiracetam necessary liver significant pharmacokinetic interactions observed levetiracetam major metabolite concomitant pharmacokinetic profile levetiracetam influenced phenytoin phenobarbital primidone carbamazepine valproic acid lamotrigine gabapentin digoxin ethinylestradiol exact mechanism levetiracetam acts treat epilepsy unknown levetiracetam exhibit pharmacologic actions similar classical anticonvulsants inhibit voltagedependent na channels affect gabaergic transmission bind gabaergic glutamatergic however drug binds synaptic vesicle glycoprotein inhibits presynaptic calcium reducing neurotransmitter release acting neuromodulator believed impede impulse conduction across absorption levetiracetam tablets oral solution rapid essentially complete bioavailability levetiracetam close percent effect food absorption volume distribution levetiracetam similar total body water levetiracetam modestly binds plasma proteins less levetiracetam undergo extensive metabolism metabolites formed active exert pharmacological activity metabolism levetiracetam liver cytochrome enzymes metabolic pathways hydrolysis persons normal kidney function levetiracetam eliminated body primarily kidneys percent original drug passed unchanged urine plasma halflife levetiracetam adults hours although mean csf half life approx hours better reflects levels site brivaracetam chemical analogue levetiracetam racetam derivative similar properties levetiracetam available regular extended release oral formulations intravenous immediate release tablet available generic united states since uk since patent extended release tablet expire branded version keppra manufactured ucb pharmaceuticals aprecias orally disintegrating tablet form drug approved fda trade name said drug improved printing formula used improved disintegration levetiracetam schedule substance australia poisons standard february schedule substance classified prescription medicine prescription animal remedy substances use supply order persons permitted state territory legislation prescribe available pharmacist japanese law levetiracetam racetams brought country except personal use traveler travelers plan bring months worth must apply import certificate known yakkan shoumei 薬監証明 yakkan levetiracetam studied past treating symptoms neurobiological conditions tourette anxiety however serious adverse effects behavioral benefitrisk ratio conditions well levetiracetam tested drug reduce hyperactivity hippocampus alzheimers additionally levetiracetam experimentally shown reduce levodopainduced type movement disorder dyskinesia associated use levodopa medication used treat parkinsons disease medications evaluated systematic review literature levetiracetam found medication sufficient evidence showing may cause seizure freedom adverse effects levetiracetam rarely severe enough medication discontinued age group available research included published studies reporting seizure freedom rates however strength evidence judged httpsenwikipediaorgwikilevetiracetam